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Introduction
Androgen signalling through the androgen receptor is crucial for human prostate growth and function; however, excessive androgen signalling within the prostate is implicated in prostate cancer development and progression (Kaarbo et al., 2007) . The prostate has all the essential steroidogenic enzymes necessary to produce active androgens locally from circulating adrenal precursor sex steroids. For example, testosterone can be synthesized in the prostate from either androstenedione by 17β-hydroxysteroid dehydrogenase (HSD) or androst-5-ene-3β,17β-diol by 3β-HSD/(∆ 5 /∆ 4 isomerase), and it can be further transformed into the most potent androgen 5α-dihydrotestosterone (DHT) by 5α-reductase (Labrie et al., 2005) . In addition, the prostate also expresses steroid metabolizing enzymes, including DHT-inactivating enzymes . The expression of 3α-HSD and 17β-HSD within the prostate permits the local interconversion between DHT and its metabolites androsterone (ADT), 5α-androstane-3α,17β-diol (3α-diol), and 5α-androstane-3β,17β-diol (3β-diol) (Labrie et al., 2005) . This pathway is considered to be reversible and is at least partially depending on the redox status within the cellular context. The influence of this pathway on the intracellular levels of active androgens within the prostate has not yet been fully investigated. However, the expression of UGT2B15 and UGT2B17, two major androgen-conjugating enzymes from the UGT superfamily, leads to the irreversible inactivation of DHT and its metabolites within the prostate through glucuronidation (Chouinard et al., 2004) .
UGT2B15 and UGT2B17 are 95% identical in amino acid sequence but possess unique substrate specificities towards 5α-reduced androgens (Turgeon et al., 2000) . UGT2B17
conjugates both the 3-and -17-hydroxy positions of androgens, such as the 3-OH of ADT and the 17-OH of 3α-diol or DHT, whereas UGT2B15 specifically glucuronidates the 17-hydroxy This article has not been copyedited and formatted. The final version may differ from this version. position of androgens, including the 17-OH of 3α-diol and DHT (Dubois et al., 1999; Turgeon et al., 2001 ). In the prostate, UGT2B17 is expressed in the basal cells of the alveoli and is thought to be involved in glucuronidation of DHT, ADT and 3α-diol in these cells, whereas UGT2B15 is exclusively expressed in the luminal cells, where it only inactivates DHT, as the enzymes for the formation of ADT and 3α-diol are not present in these cells . As glucuronidation of androgens and their metabolites facilitates their excretion, UGT2B15 and 2B17 help reduce intracellular DHT concentrations and consequently prevent excessive androgen signalling within the prostate (Chouinard et al., 2008) . Indeed, it has been recently shown that the glucuronidation of androgens by UGT2B15 and 2B17 is a major determinant of the androgen response in prostate cancer LNCaP cells as evidenced by the reported enhanced expression of androgen target genes in UGT2B15/17-deficient cells compared to control cells in the presence of DHT (Chouinard et al., 2007) .
Given the crucial role of UGT2B15 and 2B17 enzymes in the local inactivation of active androgens, it is important to decipher the molecular mechanism (s) that regulate their expression within the prostate. Accumulating evidence strongly suggests that the expression of the human UGT2B15 and 2B17 genes are negatively regulated at the transcriptional level by a number of endogenous and exogenous ligands in Androgen Receptor (AR)-positive human prostate cancer cell lines. These include AR-mediated suppression of UGT2B15 and 2B17 expression by natural (DHT) and synthetic (R1881) androgens (Chouinard et al., 2006; Bao et al., 2008) , the farnesoid X receptor-mediated repression by farnesoid X receptor activators such as chenodeoxylcholic acid, GW40, and androsterone (Kaeding et al., 2008b) , and the vitamin D receptor-mediated down-regulation by Calcitriol (1α, ), the active metabolite of vitamin D (Kaeding et al., 2008a) . However, in contrast to these effects of ligands, the mechanisms regulating basal UGT2B15 and 2B17 gene expression are poorly understood.
This article has not been copyedited and formatted. The final version may differ from this version. (Mincheva et al., 1997; Myatt and Lam, 2007 ). FOXA1 appears to act as a transcriptional facilitator by binding to its cognate response elements as a monomer in the regulatory regions of target genes and enhancing the access of other transcription factors (Lupien et al., 2008) .
We recently reported that FOXA1 is a major regulator of the basal expression of UGT2B17 gene in prostate cancer cell lines (Hu et al.) . In this study we report that FOXA1 is also essential for the basal transcriptional activity of the UGT2B15 gene in LNCaP cells.
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Materials and Methods
Generation of UGT2B15 Promoter Luciferase Reporter Deletion Constructs and Mutants:
Sixteen pGL3-derived luciferase reporter constructs carrying varying lengths of the UGT2B15 proximal promoter were used in transient transfection in the present study (Fig. 1) . Fourteen of these constructs were previously reported, namely 2B15-2716/-3Luc, 2B15-747/-3Luc, 2B15-705/-3Luc, 2B15-595/-3Luc, 2B15-556/-3Luc, 2B15-458/-3Luc, 2B15-412/-3Luc, 2B15-361/-3Luc, 2B15-310/-3Luc, 2B15-253/-3Luc, 2B15-202/-3Luc, 2B15-154/-3Luc, 2B15-101/-3Luc, and 2B15-54/-3Luc (Hu and Mackenzie, 2009) . The other two constructs were generated with the construct 2B15-747/-3Luc as template. The UGT2B15 promoter regions from nucleotides -3 to -511 and -3 to -648 were amplified by PCR using the forward primers 2B15-511For 5'-AGCCATGGTACCGTGAAAGTAAAATTCTGT-3' and 2B15-648For 5'-AGCCATGGTACCAAGGGTCCAGAAAATGC-3', respectively, and the common reverse primer as previously reported (Hu and Mackenzie, 2009) Cruz Biotechnology (Santa, Cruz, CA). EMSA experiments were carried out essentially as reported elsewhere (Hu and Mackenzie, 2009 ).
Chromatin Immunoprecipitation Assay and Quantitative Real-Time PCR (ChIP-qPCR):
ChIP-qPCR was performed as reported elsewhere (Hu and Mackenzie, 2009 ). In brief, LNCaP cells were grown in RPMI medium supplemented with 5% FBS. When culture reached 90%
confluence, cells were crossed linked by 1% formaldehyde and subsequently quenched by 125 mM glycine solution. Cells were lysed, sonicated, and then subjected to immnuoprecipitation with 10 μg of each specific antibody or equivalent amounts of the rabbit preimmune IgG control.
The resulting chromatin precipitates were captured by protein A Sepharose CL-4B beads (GE Healthcare), and subsequently were eluted from these beads following several washes in different buffers as reported (Hu and Mackenzie, 2009 ). Cross-linking was reversed by heating the eluates at 65°C overnight. The resulting DNA/protein precipitates were digested with proteinase K, followed by phenol-chloroform extraction and ethanol precipitation. The DNA pellets were dissolved in 50 μ l of Tris-EDTA buffer. Quantitative real-time PCR (qPCR) was performed with 2 μ l of each of the resultant DNA samples as templates and locus-specific primers. qPCR primers for both the UGT2B15 promoter (Hu and Mackenzie, 2009) (reverse) for GAPDH. Those for UGT2B15 and 18S rRNA were the same as previously reported (Congiu et al., 2002) . Data from 18S rRNA transcripts were used as a reference to normalize the amount of total RNA amplified in each reaction.
Results and Discussion
As the UGT2B15 and UGT2B17 genes share considerable sequence homology between their proximal promoters ( Fig. 1) , it is likely that they are regulated by some transcription factors in common. We have recently shown that FOXA1 regulates the basal activity of the UGT2B17 promoter in LNCaP cells (Hu et al.) . We have also shown that a single base change (the A/G SNP at -155 bp) within the UGT2B17 FOXA1 site can alter promoter activity up to 13-fold. Although the equivalent putative FOXA1 site of the UGT2B15 promoter does not contain this particular SNP, it does differ by a single base to that of UGT2B17 (Fig. 1) . As single base changes can diminish FOXA1 binding and substantially reduce promoter activity, it was necessary to confirm that the UGT2B15 promoter was active and was regulated by FOXA1. It was also important to determine whether other sites in the UGT2B25 proximal promoter were involved in control of basal UGT2B15 promoter activity.
For this purpose, a series of sixteen luciferase reporter constructs carrying varying lengths of the UGT2B15 proximal promoter were generated. As shown in (Fig. 2) . To further verify its functionality, we mutated this FOXA1 site in another construct 2B15-458/-3Luc to create the mutant 2B15-458/FOXA1-MT/-3Luc. When transfected into LNCaP cells, this mutation also resulted in a large reduction in promoter activity compared to its wild-type counterpart (p < 0.01) (Fig. 2) . Altogether, these results clearly demonstrate that basal UGT2B15 promoter activity is dependent on an intact FOXA1 site, and that transcription factors which bind outside this region, do not have a major role in basal UGT2B15 expression in LNCaP cells, under our experimental conditions.
There are three FOXA proteins, A1, A2 and A3, which bind to the same consensus sequence (Lai et al., 1990; Lai et al., 1991) . However, as only FOXA1 protein expression has been demonstrated in LNCaP cells (Mirosevich et al., 2006) , we undertook EMSAs to see whether FOXA1 bound to the UGT2B15 FOXA1 site using in vitro transcribed/translated recombinant FOXA1 protein.
Incubation of a UGT2B15 promoter probe (nucleotides -222 to -188) containing the putative FOXA1 site with recombinant FOXA1 protein led to the formation of a FOXA1-specific protein/DNA complex (labelled A) (Fig. 3A, lane 2) , as evidenced by the formation of the supershifted complex (labelled SS) upon the addition of the anti-FOXA1 antibody (Fig. 3A, lane   4) . Furthermore, the absence of complex A in the negative control (Fig. 3A, lane 1) , as well as disruption of this complex in competition assays in the presence of a 100-fold molar excess of unlabelled probe (Fig. 3A, lane 3) , provide further evidence that FOXA1 binds to its cognate site in the UGT2B15 promoter. To prove the direct involvement of the putative FOXA1 site in the an approximately 3-fold decrease in UGT2B15 mRNA levels (p < 0.001), whereas there was no significant effect on the mRNA levels of the negative control, glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Taken together, these siRNA silencing experiments strongly suggest that FOXA1 has a positive regulatory role in UGT2B15 gene transcription in LNCaP cells.
In summary, the present study identifies a functional FOXA1 site within the proximal UGT2B15 promoter that is important for basal UGT2B15 gene transcriptional activity in LNCaP cells. Although differing by one base to the equivalent site in the UGT2B17 gene, the UGT2B15
FOXA1 site is closer in sequence to the high activity UGT2B17 promoter allele (-155A) and thus sustains significant promoter activity. Hence, our results show for the first time that FOXA1, a pioneering transcription factor (Lupien et al., 2008) , plays a crucial role in controlling basal expression of UGT2B15 in prostate cancer cells. Together with our previous demonstration of the importance of FOXA1 in regulating basal UGT2B17 gene expression (Hu et al.) , these findings provide new insights into our understanding of the molecular mechanisms that determine androgen glucuronidation capacity and hence androgen homeostasis and signalling in the prostate. As UGT2B15 and UGT2B17 are the major enzymes inactivating and eliminating active androgens by glucuronidation, the control of UGT2B15 gene expression by FOXA1 would be of particular significance for individuals homozygous for the UGT2B17 deletion, where UGT2B15
is the only enzyme in this organ with the capacity to effectively glucuronidate active androgens (McCarroll et al., 2006) . 
